Crinetics Pharmaceuticals Announces Phase 2 ACROBAT Edge Study with Paltusotine in Acromegaly Met Primary Endpoint

NEXT STORY
Preeclampsia Diagnostics Market to Exhibit 11.0% CAGR and Touch USD 2.52 Billion by 2027; Increasing Healthcare Expenditure to Boost Growth: Fortune Business Insights™
PREV STORY
ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sorrento Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in ICU Patients

author_avatar
NASDAQ Market News

ADMA Biologics Expands Global Regulatory Approval Presence and Announces FDA Approval to Commence Hepatitis B Plasma Collections

author_avatar
NASDAQ Market News

TESARO Announces Submission of Investigational New Drug Application for Anti-TIM-3 Antibody TSR-022 to the U.S. FDA

WALTHAM, Mass., April 25, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical ...

author_avatar
NASDAQ Market News